Agreement Includes 10-Year Brand and Generic Distribution Contract
with Walgreens and Access to Generics Sourced Through Walgreens Boots
Alliance Development GmbH Joint Venture
VALLEY FORGE, Pa.--(BUSINESS WIRE)--Mar. 19, 2013--
AmerisourceBergen (NYSE: ABC) today announced that it is entering into a
strategic, long-term relationship with Walgreen Co. and Alliance Boots
GmbH, which will streamline the distribution of pharmaceuticals to
Walgreensâ stores and leverage global supply chain efficiencies while
improving patient access to affordable pharmaceuticals to increase the
efficiency of the healthcare system. AmerisourceBergenâs new expanded
relationship with Walgreens and Alliance Boots includes: a ten-year
comprehensive primary pharmaceutical distribution contract with
Walgreens; access to generic drugs and related pharmaceutical products
through the Walgreens Boots Alliance Development joint venture; and
opportunities to accelerate the Companyâs efforts to grow its specialty
and manufacturer services businesses domestically and internationally.
In furtherance of this new partnership, Walgreens and Alliance Boots
together have been granted rights to purchase an equity position in
AmerisourceBergen, which is described in greater detail below.
The new agreements are expected to be meaningfully accretive to
AmerisourceBergenâs earnings and strengthen its confidence in delivering
solid and sustainable long-term EPS growth. AmerisourceBergen has
serviced Walgreensâ specialty business for several years, and in our
fiscal 2014, the new relationship is expected to contribute an
incremental $28 billion in revenues and approximately 20 cents in
earnings per share, excluding the amortization of certain expenses
related to the transaction, and certain non-recurring costs, and net of
certain start up expenses.
âAmerisourceBergen is very excited to be joining in this unique global
relationship with two of the undisputed leaders in healthcare,â said
Steven H. Collis, President and Chief Executive Officer of
AmerisourceBergen. âAs we all recognize the imperatives of health reform
not only here in the U.S. but also globally, we have entered into a
unique opportunity to unlock value in the pharmaceutical supply chain by
collaborating to leverage all of our proven strengths. This new
relationship will significantly strengthen and grow our core business
and increase our ability to deliver innovative solutions to our
customers, and long-term benefits to all of our stakeholders.
Importantly, these agreements not only expand our U.S. business, but
also provide opportunities to meaningfully grow our specialty and
manufacturer services businesses internationally."
âTodayâs announcement marks another step forward in establishing an
unprecedented and efficient global pharmacy-led, health and wellbeing
network, and achieving our vision of becoming the first choice in health
and daily living for everyone in America and beyond,â said Gregory
Wasson, President and Chief Executive Officer of Walgreens. âWe are
excited to be expanding our existing relationship with AmerisourceBergen
to a ten-year strategic long-term contract, representing another
transformational step in the pharmaceutical supply chain. We believe
this relationship will create a wide range of opportunities and
innovations in the rapidly changing U.S. and global healthcare
environment that we expect will benefit all of our stakeholders.â
âThis agreement with AmerisourceBergen, which we consider to be the
best-positioned pharmaceutical wholesaler in North America, is a
promising development for Walgreens and Alliance Boots following the
formation of our strategic partnership last year,â said Stefano Pessina,
Executive Chairman of Alliance Boots. âWe strongly believe that our new
partnership with AmerisourceBergen will deliver long-term shareholder
value by creating an unmatched network of companies that is well
positioned to anticipate increasing market needs and expectations across
the world. Together we will bring tailored solutions to business
partners, including manufacturers and pharmacists, as well as to
patients and consumers.â
Branded and Generic Pharmaceutical Distribution
Contract
The ten-year comprehensive primary pharmaceutical supply agreement
includes the distribution of brand, generic, and specialty
pharmaceuticals to Walgreensâ retail stores, mail order and specialty
pharmacies. The distribution contract is effective September 1, 2013,
and initially will include branded pharmaceutical products that
Walgreens has historically sourced from distributors and suppliers. Over
time, beginning in calendar year 2014, AmerisourceBergen will
increasingly assume the distribution of the generic products that
Walgreens has historically self-distributed. The increased volume will
utilize unused capacity in AmerisourceBergenâs distribution network,
leverage prior investments in our new enterprise resource planning
system, and will help continue to drive improvements in operational
efficiency and productivity in the years ahead.
Global Supply Chain Opportunities
AmerisourceBergenâs access to the recently established Walgreens Boots
Alliance Development enables the Company to access generics and related
pharmaceutical products utilizing a global platform that is designed to
make it easier for manufacturers to bring products to market, improve
access to pharmaceuticals for healthcare providers worldwide, and yields
compelling new offerings to community pharmacies and others. In
addition, we expect to share global distribution best practices with
Walgreens and Alliance Boots, and to seek additional avenues for
collaboration on new projects and services for the benefit of all of our
stakeholders.
Opportunities to Expand Specialty and
Manufacturer Services Businesses
In addition to the pharmaceutical supply contracts, AmerisourceBergen
has agreed to collaboratively share best practices and to cooperatively
work with Walgreens and Alliance Boots to provide manufacturers with
integrated solutions for global clinical trial logistics and innovative
global third party logistics services by leveraging World Courierâs
position as a global leader in premium logistics. In addition, Alliance
Bootsâ growing specialty activities with European biotech manufacturers
and AmerisourceBergenâs pharmaceutical product commercialization and
patient support services offer manufacturers unique opportunities to
expand patient access to biotech products in Europe and beyond.
Equity Position
As part of the value creation inherent in these agreements and to align
interests and strengthen the long-term relationship, Walgreens and
Alliance Boots together have been granted the right to purchase a
minority equity position in AmerisourceBergen, beginning with the right
to purchase up to 7 percent of the fully diluted equity of
AmerisourceBergen in the open market. In addition, AmerisourceBergen has
granted to Walgreens and Alliance Boots equity warrants exercisable for
16 percent in the aggregate of the fully diluted equity of
AmerisourceBergen. The first tranche of warrants, representing 8 percent
of the fully diluted equity of AmerisourceBergen, has a strike price of
$51.50 and will be exercisable for a six-month period beginning in March
2016. The second tranche of warrants, also representing 8 percent of the
fully diluted equity of AmerisourceBergen, has a strike price of $52.50
and will be exercisable for a six-month period beginning in March 2017.
The warrants will be allocated equally among Walgreens and Alliance
Boots. Walgreens and Alliance Boots have agreed to customary transfer
restrictions on their equity stake, and have also agreed not to acquire
additional equity of AmerisourceBergen under the terms of a standstill
agreement, subject to the terms and conditions of such agreement,
including certain pre-emption rights and permitted exceptions.
Walgreens will have the ability to appoint one director to
AmerisourceBergenâs board upon Walgreens and Alliance Boots together
acquiring a 5 percent equity stake, and a second director upon exercise
in full of the first warrants. These new board seats will add to the
Companyâs current nine-member board.
Regulatory Approvals Required
The equity investment by Walgreens and Alliance Boots is subject to the
receipt of customary regulatory approvals.
Revised Guidance for Fiscal 2013
As a result of this new relationship, the Company expects incremental
brand revenues of at least $2 billion in September of 2013, and we have
increased our guidance for revenue growth to 8 percent to 11 percent for
the full fiscal year. The company has revised its expectations for GAAP
earnings per share from continuing operations for fiscal 2013 to a range
of $2.96 to $3.06, as certain one-time start up operational expenses and
transaction costs will more than offset the addition of the new business
late in our fiscal fourth quarter. The revised range does not include
the impact of a significant one-time LIFO expense due to the inventory
build anticipated in relation to the new business, or an intangible
amortization expense related to the equity warrants. We expect to have
additional information available on the LIFO and amortization expenses,
the expected decline in operating margins and other items when we report
results for our March fiscal quarter.
The Company had previously expected free cash flow for fiscal 2013 to be
in the range of $750 to $850 million, and now expects that range to
decrease significantly to $100 to $200 million as we onboard the new
business, and incur an additional $40 million in related capital
expenses.
Conference Call
The Company will host a conference call today at 7:30 a.m. Eastern
Daylight. Participating in the conference call will be: Steven H.
Collis, President and Chief Executive Officer of AmerisourceBergen; and
Tim G. Guttman, Senior Vice President and Chief Financial Officer of
AmerisourceBergen. In addition, Gregory Wasson, President and Chief
Executive Officer of Walgreens, and Stefano Pessina, Executive Chairman
of Alliance Boots, will be our special guests on the conference call.
To access the live conference call via telephone:
Dial
in: The dial-in number for the live call will be (612) 326-1011. No
access code is needed.
To access the live webcast:
Go to the
Investor Relations page at http://www.amerisourcebergen.com.
A replay of the telephone call and webcast will be available from 10:30
a.m.March 19, 2013 until 11:59 p.m.March 26, 2013. The Webcast replay
will be available for 30 days.
To access the telephone replay from within the US, dial 800-475-6701.
From outside the US, dial 320-365-3844. The access code for the replay
is 286668.
To access the archived webcast, go to the Quarterly Webcasts section on
the Investor Relations page at http://www.amerisourcebergen.com.
Additional Information
AmerisourceBergen intends to promptly file with the Securities and
Exchange Commission a current report on Form 8-K, which will include the
Framework Agreement, Warrants and Shareholders Agreement. You should
refer to the Form 8-K when it is available for more detailed information
regarding this strategic transaction between AmerisourceBergen,
Walgreens, and Alliance Boots and related matters.
About AmerisourceBergen
AmerisourceBergen is one of the world's largest pharmaceutical services
companies serving the United States, Canada and selected global markets.
Servicing both healthcare providers and pharmaceutical manufacturers in
the pharmaceutical supply channel, the Company provides drug
distribution and related services designed to reduce costs and improve
patient outcomes. AmerisourceBergen's service solutions range from niche
premium logistics and pharmaceutical packaging to reimbursement and
pharmaceutical consulting services. With over $80 billion in annualized
revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and
employs approximately 13,000 people. AmerisourceBergen is ranked #29 on
the Fortune 500 list. For more information, go to www.amerisourcebergen.com.
AmerisourceBergenâs Cautionary Note Regarding
Forward-Looking Statements
Statements in this release that are not historical are forward-looking
statements made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Words such as âexpect,â
âlikely,â âoutlook,â âforecast,â âwould,â âcould,â âshould,â âcan,â
âwill,â âproject,â âintend,â âplan,â âcontinue,â âsustain,â âsynergyâ,
âon track,â âbelieve,â âseek,â âestimate,â âanticipate,â âmay,â
âpossible,â âassume,â variations of such words and similar expressions
are intended to identify such forward-looking statements. These
statements are based on managementâs current expectations and are
subject to uncertainty and changes in circumstances. These
forward-looking statements are not guarantees of future performance, are
based on assumptions that could prove incorrect or could cause actual
results to vary materially from those indicated, and are subject to
risks and uncertainties, including the failure to obtain the required
U.S. and foreign antitrust regulatory approvals for the equity
investments by Walgreens and Alliance Boots in AmerisourceBergen, the
occurrence of any event, change or other circumstance that could give
rise to the termination, cross-termination or modification of any of the
transaction documents, including, among others, the distribution
agreement or the generics agreement, an impact on AmerisourceBergenâs
earnings per share resulting from the exercise of the warrants, the
disruption of AmerisourceBergenâs plans and operations as a result of
the transaction, the inability to realize anticipated synergies,
including synergies resulting from participation in the Walgreens Boots
Alliance Development GmbH joint venture,potential operating
dis-synergies, disruption resulting from potential vendor, payor and
customer reaction to the transaction, the inability to achieve
anticipated financial results, unexpected costs, fees, expenses and
charges incurred by AmerisourceBergen related to the transaction, the
disruption of AmerisourceBergenâs cash flow and ability to return value
to its stockholders in accordance with its past practices, risks
associated with international business operations, changes in vendor,
payer and customer relationships and terms, the reduction of
AmerisourceBergenâs operational, strategic or financial flexibility, and
other factors described in Item 1A (Risk Factors) of our most recent
Annual Report on Form 10-K and Quarterly Report on Form 10-Q, each of
which is incorporated herein by reference, and in other documents that
we file or furnish with the Securities and Exchange Commission. Should
one or more of these risks or uncertainties materialize, or should
underlying assumptions prove incorrect, actual results may vary
materially from those indicated or anticipated by such forward-looking
statements. Accordingly, you are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date
they are made. Except to the extent required by law, AmerisourceBergen
does not undertake, and expressly disclaims, any duty or obligation to
publicly update any forward-looking statement after the date of this
report, whether as a result of new information, future events, changes
in assumptions or otherwise.
Source: AmerisourceBergen
AmerisourceBergen
Barbara Brungess, 610-727-7199
bbrungess@amerisourcebergen.com